Invitae Corporation (NYSE:NVTA) Files An 8-K Other Events
Item 8.01 Regulation FD Disclosure.

Invitae Corporation (the “Company”) is filing an investor presentation attached hereto as Exhibit 99.1, which is incorporated herein by reference.

(d) Exhibits

Reference is made to the Exhibit Index included with this Current Report on Form 8-K.

Invitae Corp Exhibit
EX-99.1 2 d440213dex991.htm EX-99.1 EX-99.1 Q2 2017 conference call Invitae: Genetics from downstream to mainstream Exhibit 99.1 Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,…
To view the full exhibit click here

About Invitae Corporation (NYSE:NVTA)

Invitae Corporation (Invitae) utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. The Company offers panels for over 120 conditions in hereditary cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. It has developed an offering that enables healthcare professionals to customize a test and receive test results at requisition.